We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

200 hedge funds and large institutions have $5.01B invested in Intercept Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 78 increasing their positions, 53 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 23

107% more capital invested

Capital invested by funds: $2.42B → $5.01B (+$2.58B)

47% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 53

18% more funds holding

Funds holding: 169200 (+31)

14% more call options, than puts

Call options by funds: $257M | Put options by funds: $225M

Holders
200
Holders Change
+31
Holders Change %
+18.34%
% of All Funds
5.33%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
54
Increased
78
Reduced
53
Closed
23
Calls
$257M
Puts
$225M
Net Calls
+$31.7M
Net Calls Change
+$71.9M
Name Holding Trade Value Shares
Change
Change in
Stake
RIM
51
Rainier Investment Management
Washington
$12.3M -$43.3K -200 -0.5%
Allianz Asset Management
52
Allianz Asset Management
Germany
$12.1M -$6.5K -30 -0.1%
GC
53
Guggenheim Capital
Illinois
$11.6M -$2.08M -9,596 -19%
EMFAT
54
Emerald Mutual Fund Advisers Trust
Pennsylvania
$10.4M -$309K -1,428 -4%
RSCM
55
Rock Springs Capital Management
Maryland
$10.2M +$4.24M +19,600 +120%
DCM
56
Driehaus Capital Management
Illinois
$10.1M +$7.77M +35,895 New
RFC
57
Russell Frank Company
Washington
$9.94M -$14.2M -65,517 -65%
AGC
58
Alden Global Capital
Florida
$9.9M +$7.6M +35,100 New
GL
59
GLG LLC
New York
$9.52M +$7.31M +33,761 New
SDIC
60
South Dakota Investment Council
South Dakota
$9.5M -$1.26M -5,800 -15%
D.E. Shaw & Co
61
D.E. Shaw & Co
New York
$9.19M +$7.05M +32,570 New
TAM
62
Tocqueville Asset Management
New York
$9.02M +$4.11M +18,990 +146%
SCM
63
Suffolk Capital Management
New York
$9M -$9.46M -43,691 -58%
LI
64
LMCG Investments
Massachusetts
$8.9M +$3.4M +15,700 +99%
State of Tennessee, Department of Treasury
65
State of Tennessee, Department of Treasury
Tennessee
$8.79M +$6.75M +31,156 New
VanEck Associates
66
VanEck Associates
New York
$8.62M +$393K +1,816 +6%
Charles Schwab
67
Charles Schwab
California
$8.14M +$847K +3,909 +16%
FCM
68
Frontier Capital Management
Massachusetts
$7.26M -$1.07M -4,925 -16%
Invesco
69
Invesco
Georgia
$7.18M -$20.1M -92,674 -78%
WMSA
70
Weiss Multi-Strategy Advisers
New York
$7.05M -$455K -2,100 -8%
Janus Henderson Group
71
Janus Henderson Group
United Kingdom
$7.05M +$5.41M +25,000 New
California State Teachers Retirement System (CalSTRS)
72
California State Teachers Retirement System (CalSTRS)
California
$6.9M +$260K +1,200 +5%
PAMU
73
Pictet Asset Management (UK)
United Kingdom
$6.67M -$2.07M -9,555 -27%
RPAM
74
Rhenman & Partners Asset Management
Sweden
$6.49M +$217K +1,000 +5%
Goldman Sachs
75
Goldman Sachs
New York
$6.16M -$6.81M -31,436 -59%

ICPT Hedge Fund Activity: Q1 2015 in Review

200 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2015, worth a combined $5.01B — up 107% from $2.42B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new ICPT positions and 23 closed out — a net gain of 31 holders — while 78 added to existing stakes and 53 trimmed.

The largest buyer was Ameriprise, adding an estimated $161M. The largest seller was OrbiMed, cutting an estimated $79M.

  • 200 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2015, up from 169 in Q4 2014.
  • Funds reported $5.01B of Intercept Pharmaceuticals, Inc. stock for Q1 2015, up 107% quarter-over-quarter.
  • 54 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2015 and 23 closed out, a net change of +31 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2015 was Ameriprise, an estimated $161M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q1 2015 was OrbiMed, an estimated $79M sold.

Based on aggregated 13F filings for Q1 2015.